home / stock / rytm / rytm news

RYTM News and Press, Rhythm Pharmaceuticals Inc. From 07/20/22

Stock Information
Company Name: Rhythm Pharmaceuticals Inc.
Stock Symbol: RYTM
Market: NASDAQ
Website: rhythmtx.com
Menu
RYTM RYTM Quote RYTM Short RYTM News RYTM Articles RYTM Message Board
Get RYTM Alerts

News, Short Squeeze, Breakout and More Instantly...
RYTM - Rhythm, Allakos top healthcare gainers; Vascular, Belite lead losers' pack

Gainers: Rhythm Pharmaceuticals ( RYTM ) +20% . Allakos ( ALLK ) +14% . Senti Biosciences ( SNTI ) +13% . Arcturus Therapeutics ( ARCT ) +7% . Verve Therapeutics ( VERV ) +5% . Losers: Vascular Biogenics ( VBLT ) -78%...
RYTM - Rhythm stock rises 20% as Imcivree gets early access nod in France for rare disorder

Rhythm Pharmaceuticals ( NASDAQ: RYTM ) stock rose ~20% on July 20 after its drug Imcivree was granted early access authorization in France for patients with genetically-confirmed Bardet-Biedl syndrome (BBS) to treat obesity and control of hunger. The company said t...

RYTM - Rhythm Pharmaceuticals Announces Early Access Authorization for Setmelanotide for Use in Patients with Bardet-Biedl Syndrome in France

-- Reimbursed early access program allows for patients in France to receive setmelanotide for treatment of obesity and control of hunger associated with BBS -- BOSTON, July 20, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical...

RYTM - Inotiv, IO Biotech top healthcare gainers; Regulus, Aerovate lead losers' pack

Gainers: Inotiv ( NOTV ) +18% . IO Biotech ( IOBT ) +16% . SOPHiA GENETICS ( SOPH ) +10% . Apyx Medical ( APYX ) +9% . Rhythm Pharmaceuticals ( RYTM ) +9% . Losers: Regulus Therapeutics ( RGLS ) -14% . Aerovate...
RYTM - Rhythm Pharma gains as NICE recommends obesity drug

The commercial stage biotech Rhythm Pharmaceuticals ( NASDAQ: RYTM ) added 7% in the pre-market Monday after the company announced that the U.K.’s National Institute for Health and Care Excellence (NICE) recommended its weight loss therapy Imcivree (setmelanotide). ...

RYTM - NICE Recommends Rhythm's ?IMCIVREE® (setmelanotide) for Treating Obesity and Controlling Hunger Caused by POMC or LEPR Deficiency

- IMCIVREE will be funded and available for use within 90 days in the National Health Service - BOSTON, July 18, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their...

RYTM - Rhythm Pharma extends gains to reach three-month high

The shares of commercial stage biotech Rhythm Pharmaceuticals ( NASDAQ: RYTM ) rose sharply for the second straight session on Wednesday to approach the highest level since mid-April as Wall Street reacts to the company’s Phase 2 data for setmelanotide in hypothalamic o...
RYTM - XORTX Therapeutics leads healthcare gainers, Humanigen and Atara Biotherapeutics among losers

Gainers: XORTX Therapeutics ( XRTX ) +39% . Gossamer Bio ( GOSS ) +24% . Rhythm Pharmaceuticals ( RYTM ) +23% . Apollo Endosurgery ( APEN ) +18% . Tyra Biosciences ( TYRA ) +15% . Losers: Humanigen ( HGEN ) -80% . Atara Biotherap...

RYTM - Fastenal, Unity Software, MSP Recovery among premarket losers' pack

Humanigen HGEN -68% as trial for COVID-19 therapy fails . Atara Biotherapeutics ATRA -46% on interim analysis of phase 2 study for multiple sclerosis candidate. TherapeuticsMD TXMD -41% as merger agreement ends . Helius Medical Technologies ( HSDT...

RYTM - Rhythm stock rises 9% as obesity therapy setmelanotide helps reduce BMI in mid-stage study

Rhythm Pharmaceuticals ( NASDAQ: RYTM ) said its medicine setmelanotide helped reduce Body Mass Index (BMI) in patients with severe obesity and hyperphagia (excessive hunger) in people living with hypothalamic obesity as per interim data from a phase 2 trial. H...
Previous 10 Next 10